We are live on ! Find out more
KTTAW icon

Pasithea Therapeutics Warrants
KTTAW

4 hedge funds and large institutions have $579K invested in Pasithea Therapeutics Warrants in 2021 Q4 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 1

33% more funds holding

Funds holding: 3 → 4 (+1)

48% less capital invested

Capital invested by funds: $1.12M → $579K (-$541K)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
4
Holders Change
+1
Holders Change %
+33.33%
% of All Funds
0.06%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
–
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
WAM
Warberg Asset Management
Illinois
+$108K
2
HF
HRT Financial
New York
+$6.15K

Top Sellers

Rank Fund Capital Flow
1
KC
Kepos Capital
New York
-$32.2K
Name Holding Trade Value Shares
Change 		Change in
Stake
AC
1
Armistice Capital
New York
$370K – – –
KC
2
Kepos Capital
New York
$124K -$32.2K -65,400 -16%
WAM
3
Warberg Asset Management
Illinois
$81K +$108K +218,920 New
HF
4
HRT Financial
New York
$4K +$6.15K +12,483 New

KTTAW Hedge Fund Activity: Q4 2021 in Review

4 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Pasithea Therapeutics Warrants (KTTAW) for Q4 2021, worth a combined $579K — down 48% from $1.12M a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new KTTAW positions and 1 closed out — a net gain of 1 holder — while 0 added to existing stakes and 1 trimmed.

The largest buyer was Warberg Asset Management, opening a new position worth an estimated $108K. The largest seller was Kepos Capital, cutting an estimated $32.2K.

  • 4 institutional investors held Pasithea Therapeutics Warrants (KTTAW) as of Q4 2021, up from 3 in Q3 2021.
  • Funds reported $579K of Pasithea Therapeutics Warrants stock for Q4 2021, down 48% quarter-over-quarter.
  • 2 funds opened new Pasithea Therapeutics Warrants positions in Q4 2021 and 1 closed out, a net change of +1 holder.
  • The largest Pasithea Therapeutics Warrants buyer in Q4 2021 was Warberg Asset Management, an estimated $108K added.
  • The largest Pasithea Therapeutics Warrants seller in Q4 2021 was Kepos Capital, an estimated $32.2K sold.

Based on aggregated 13F filings for Q4 2021.